Immunocine Cancer Center

13/02/2026

Whether you’ve followed Immunocine from the start or are just joining us, we’re grateful you’re here.

Our CEO and founder, Matt Halpert, delivered a welcome speech at the recent Immunocine Summit that serves as a great (re-)introduction for who we are.

At Immunocine, we’re focused on a fundamental problem in cancer care: many patients don’t have an immune system that’s effectively responding to their cancer. Rather than concentrating only on what causes cancer, we’re asking why the immune system isn’t eliminating it, and how we can help change that.

That starts with the science. And the Immunocine Dendritic Cell Treatment (IDCT) protocol. This is the first treatment of its kind to “Double Load” the patient’s Dendritic Cells with their extracted cancer cells. Using this completely new approach, our treatment is able to not only generate a natural immune response, but one that is comprehensive enough to attack a patient’s cancer throughout their body.

The future of cancer treatment is right here, right now.

07/02/2026

A big thank you to our amazing team and partners who presented at the Immunocine Summit. It’s so important that our community hears directly from the people doing the work and driving what’s next at Immunocine. We can’t wait to share more of their insights with all of you in the weeks to come.

06/02/2026

A great start to the year with our team, our patients, and our extended Immunocine community at the Immunocine Summit in Cancun this past weekend! We’re grateful for the chance to connect, listen, and engage in meaningful conversations about our treatment approach and patient care. Hearing diverse perspectives and sharing what’s next for Immunocine made this time especially energizing. So much to look forward to.

05/02/2026

Immunocine’s treatment is truly one-of-a-kind, and we know you might have questions about how it works. In this video, Dr. Matt Halpert breaks down what makes our Immunocine Dendritic Cell Treatment (IDCT) protocol unique.

We answer even more of your FAQs about Immunocine on our YouTube channel.

02/02/2026

In today’s world, chronic inflammation is an ever-present challenge linked to serious diseases, notably cancer. However, the paradox arises when we consider immunotherapy—a treatment harnessing inflammation to combat cancer. The key to understanding this complex interplay lies in precise “targeting” of the immune system’s arsenal.

Taken all together, the concept of “inflammation” is not straight forward and cannot be simply lumped into a “helpful” or “hurtful” category.

Read the full article here: https://immunocine.com/inflammation-in-cancer/

30/01/2026

Pete began questioning how such a large tumor was able to grow in his body undetected. It’s a great question. In searching for answers, he focused on ways to train his body to work with him — not against him — in the fight against cancer. Learn more about the approach that he decided to take, starting with treatment at Immunocine Cancer Center.

29/01/2026

After being diagnosed with a Grade 4 diffuse astrocytoma, Pete chose not to pursue chemotherapy or radiation. Instead, he sought a personalized, immune-based treatment approach at Immunocine Cancer Center.

He talks about how he made this decision in this powerful new testimonial, here: https://youtu.be/eILsISTYc9I

28/01/2026

In this testimonial, Pete shares his gratitude for being here today after being diagnosed with a Grade 4 diffuse astrocytoma. Following treatment at Immunocine, he’s now focused on showing others that cancer does not have to be a death sentence.

You can watch the full story, here: https://youtu.be/eILsISTYc9I

26/01/2026

In this episode of our “Patient Testimonials” we check in with Pete Sulack.

When Pete was diagnosed with a Grade 4 diffuse astrocytoma, doctors told him he had just a 1% chance of being alive in eight months.

In this testimonial, Pete shares how subtle symptoms led to a life-changing diagnosis, and why he chose a personalized, immune-based approach with Immunocine instead of conventional chemotherapy and radiation.

Using his own tumor tissue, Pete received a customized dendritic cell vaccine designed to activate his immune system and support his body’s natural ability to fight cancer. Today, he says he feels healthier than he ever has. And now, he is passionate about helping others understand that cancer does not have to be a death sentence.

Watch the full, moving interview with Pete here ⬇️

When Pete was diagnosed with a Grade 4 diffuse astrocytoma, doctors told him he had just a 1% chance of being alive in eight months.In this testimonial, Pete...

26/01/2026

In Episode 5 of Learning How to Fight Cancer, Dr. Matt Halpert sat down with Dr. Pete Sulack — a doctor, cancer patient, and survivor — to share his remarkable story of beating the odds after being given just a 1% chance to live eight months.

Throughout their conversation, Dr. Halpert and Dr. Sulack discuss the realities of navigating a terminal diagnosis, the role of faith and mindset, and the practical steps patients can take to strengthen the body against cancer.

21/01/2026

We have our own dedicated peer reviewed research published in a variety of medical and scientific journals. Matt Halpert breaks down what that really means.

We answer more of your FAQs about Immunocine on our YouTube channel.